Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 12, 2025International Journal of Molecular SciencesOpen Access

From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons

View Full Paper
Ask AI
Bookmark
Share

Authors

TRThelvia I. RamosUniversidad de las Fuerzas Armadas ESPECVCarlos A. Villacis-AguirreUniversity of ConcepciónELEmilio LamazaresUniversity of Concepción

Discussion

Loading...

Member takes

Implication

Preclinical safety assessments demonstrate bioactivity and stability of recombinant human interferons for clinical trials, indicating their potential for advanced formulations.

Key Points

  • This research aims to evaluate the structural stability and intrinsic toxicity of recombinant human interferons.
  • Conducted stability assays to assess structural stability under controlled conditions.
  • Performed acute and sub-chronic toxicity studies in rodent, non-rodent, and higher-organism animal models.
  • Analyzed bioactivity including antiviral, antiproliferative, and immunomodulatory properties.
  • Recombinant human interferons retained bioactivity and demonstrated remarkable stability.
  • No signs of toxicity were observed at doses 100 to 300 times higher than therapeutic levels.
  • Supportive data for the safety profile includes the absence of pyrogens and evidence of systemic or structural damage.

Cite This Study

Ramos et al. (2025) studied this question.

synapsesocial.com/papers/6940190c2d562116f28f631ehttps://doi.org/10.3390/ijms262411982
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multilayer Nanocarrier for Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment2024 · 1 citations
  2. 2Translating pharmacology models effectively to predict therapeutic benefit2022 · 15 citations
  3. 3Tag-mediated single-step purification and immobilization of recombinant proteins toward protein-engineered advanced materials2021 · 93 citations
  4. 4Signaling by Type I Interferons in Immune Cells: Disease Consequences2024 · 36 citations